Deep Diving into Biomarker Results From a Phase 2 Study of the CC-90001 JNK Inhibitor in NASH with Advanced Fibrosis
Time: 1:20 pm
day: Conf Day 1 Track 1 PM
Details:
- Exploring how biomarkers can inform on mechanisms of fibrosis
- Treatment of F3 NASH Subjects with the CC-90001 JNK inhibitor associated with dose-dependent reductions in multiple biomarkers of fibrosis, including ELF and PRO-C3
- Dose-dependent reductions in imaging MRE score were consistent with serum fibrosis biomarker results
- Effects of CC-90001 appeared to be mostly anti-fibrotic with little impact on imaging or biopsy measures of steatosis
